Simcere Teams Up Again With Bristol-Myers For Co-Development In China
This article was originally published in PharmAsia News
After signing a deal in deal in November 2010 for a MET-VEGFR-2 inhibitor, Simcere and BMS switch gears for a CETP inhibitor.
You may also be interested in...
With three large outcomes studies to read out interim or final results, 2012 is likely to be a pivotal year for Merck’s R&D, even as it rebalances its traditionally first-in-class emphasis to a hybrid model that also embraces best in class.
Bristol-Myers Squibb Co. has formed a partnership with Singapore-based ASLAN Pharmaceuticals Pte. Ltd. to hasten the development of an early-stage compound that it considers promising, but not core to the big pharma's focus on more advanced oncology compounds
European Society of Cardiology Congress abstract for small study suggests Roche's dalcetrapib is safe and works on plaque burden.